These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 21897294

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment.
    Penne EL, Neumann J, Klein IH, Oey PL, Bots ML, Blankestijn PJ.
    J Nephrol; 2009; 22(2):208-15. PubMed ID: 19384838
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, TNT (Treating to New Targets) Investigators.
    J Am Coll Cardiol; 2008 Apr 15; 51(15):1448-54. PubMed ID: 18402899
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment.
    Siddiqi L, Prakken NH, Velthuis BK, Cramer MJ, Oey PL, Boer P, Bots ML, Blankestijn PJ.
    Nephrol Dial Transplant; 2010 Oct 15; 25(10):3272-7. PubMed ID: 20360012
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin.
    Kühnast S, van der Hoorn JW, van den Hoek AM, Havekes LM, Liau G, Jukema JW, Princen HM.
    J Hypertens; 2012 Jan 15; 30(1):107-16. PubMed ID: 22134386
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of aliskiren in Japanese chronic kidney disease patients with hypertension.
    Sakai Y, Otsuka T, Ohno D, Murasawa T, Sato N, Mizuno K.
    Ren Fail; 2012 Jan 15; 34(4):442-7. PubMed ID: 22260457
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes.
    Paulsen L, Matthesen SK, Bech JN, Starklint J, Pedersen EB.
    J Clin Pharmacol; 2010 Jul 15; 50(7):816-22. PubMed ID: 20056802
    [Abstract] [Full Text] [Related]

  • 17. Atorvastatin reduces oxidative stress in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
    Kishi T, Hirooka Y, Shimokawa H, Takeshita A, Sunagawa K.
    Clin Exp Hypertens; 2008 Jan 15; 30(1):3-11. PubMed ID: 18214729
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?
    Navarro-Muñoz M, Bonet J, Bayés B, Lauzurica R, Blanco S, Romero R.
    Transplant Proc; 2007 Sep 15; 39(7):2259-63. PubMed ID: 17889157
    [Abstract] [Full Text] [Related]

  • 20. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.
    Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E.
    Hypertens Res; 2011 Mar 15; 34(3):308-13. PubMed ID: 21124333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.